Axsome Therapeutics Financial Statements (AXSM)
|
|
|
|
Report date
|
|
|
01.03.2022 |
28.02.2023 |
23.02.2024 |
18.02.2025 |
23.02.2026 |
|
04.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
50.0 |
270.6 |
385.7 |
638.5 |
|
708.2 |
|
Operating Income, bln rub |
|
|
-124.7 |
-179.8 |
-231.8 |
-280.6 |
-169.2 |
|
-175.6 |
|
EBITDA, bln rub |
? |
|
-124.6 |
-175.4 |
-225.0 |
-272.6 |
-168.1 |
|
-172.7 |
|
Net profit, bln rub |
? |
|
-130.4 |
-187.1 |
-239.2 |
-287.2 |
-183.2 |
|
-188.3 |
|
|
OCF, bln rub |
? |
|
-108.2 |
-116.5 |
-145.1 |
-128.4 |
-93.4 |
|
-70.7 |
|
CAPEX, bln rub |
? |
|
0.308 |
0.702 |
0.582 |
0.270 |
0.480 |
|
0.263 |
|
FCF, bln rub |
? |
|
-108.5 |
-117.2 |
-145.7 |
-128.7 |
-93.9 |
|
-71.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
124.7 |
224.6 |
476.4 |
633.0 |
760.3 |
|
831.4 |
|
Cost of production, bln rub |
|
|
0.000 |
5.20 |
26.1 |
33.3 |
47.5 |
|
52.4 |
|
R&D, bln rub |
|
|
58.1 |
57.9 |
97.9 |
187.1 |
183.3 |
|
191.2 |
|
Interest expenses, bln rub |
|
|
5.70 |
7.34 |
6.45 |
6.57 |
6.56 |
|
5.31 |
|
|
Assets, bln rub |
|
|
87.8 |
331.5 |
588.2 |
568.5 |
689.8 |
|
713.6 |
|
Net Assets, bln rub |
? |
|
15.6 |
109.6 |
191.0 |
57.0 |
88.3 |
|
54.6 |
|
Debt, bln rub |
|
|
49.7 |
94.7 |
186.4 |
193.0 |
241.3 |
|
216.7 |
|
Cash, bln rub |
|
|
86.5 |
200.8 |
386.2 |
315.4 |
322.9 |
|
305.1 |
|
Net debt, bln rub |
|
|
-36.8 |
-106.2 |
-199.8 |
-122.4 |
-81.6 |
|
-88.4 |
|
|
Ordinary share price, rub |
|
|
37.8 |
|
|
84.6 |
182.6 |
|
169.0 |
|
Number of ordinary shares, mln |
|
|
37.6 |
40.7 |
45.4 |
47.9 |
49.7 |
|
51.2 |
|
|
Market cap, bln rub |
|
|
1 421 |
0 |
0 |
4 054 |
9 086 |
|
8 654 |
|
EV, bln rub |
? |
|
1 384 |
-106 |
-200 |
3 932 |
9 004 |
|
8 565 |
|
Book value, bln rub |
|
|
16 |
40 |
126 |
-2 |
36 |
|
4 |
|
|
EPS, rub |
? |
|
-3.47 |
-4.60 |
-5.27 |
-5.99 |
-3.68 |
|
-3.68 |
|
FCF/share, rub |
|
|
-2.89 |
-2.88 |
-3.21 |
-2.69 |
-1.89 |
|
-1.39 |
|
BV/share, rub |
|
|
0.42 |
0.97 |
2.77 |
-0.04 |
0.72 |
|
0.07 |
|
|
EBITDA margin, % |
? |
|
|
-350.5% |
-83.1% |
-70.7% |
-26.3% |
|
-24.4% |
|
Net margin, % |
? |
|
|
-374.0% |
-88.4% |
-74.5% |
-28.7% |
|
-26.6% |
|
FCF yield, % |
? |
|
-7.64% |
|
|
-3.17% |
-1.03% |
|
-0.82% |
|
ROE, % |
? |
|
-834.3% |
-170.8% |
-125.3% |
-503.8% |
-207.5% |
|
-345.0% |
|
ROA, % |
? |
|
-148.5% |
-56.5% |
-40.7% |
-50.5% |
-26.6% |
|
-26.4% |
|
|
P/E |
? |
|
-10.9 |
0.00 |
0.00 |
-14.1 |
-49.6 |
|
-46.0 |
|
P/FCF |
|
|
-13.1 |
0.00 |
0.00 |
-31.5 |
-96.8 |
|
-121.9 |
|
P/S |
? |
|
|
0.00 |
0.00 |
10.5 |
14.2 |
|
12.2 |
|
P/BV |
? |
|
90.9 |
0.00 |
0.00 |
-2 110 |
254.3 |
|
2 405 |
|
EV/EBITDA |
? |
|
-11.1 |
0.61 |
0.89 |
-14.4 |
-53.6 |
|
-49.6 |
|
Debt/EBITDA |
|
|
0.29 |
0.61 |
0.89 |
0.45 |
0.49 |
|
0.51 |
|
|
R&D/CAPEX, % |
|
|
18 851% |
8 255% |
16 829% |
69 288% |
38 183% |
|
72 689% |
|
|
CAPEX/Revenue, % |
|
|
|
1.40% |
0.22% |
0.07% |
0.08% |
|
0.04% |
|
| Axsome Therapeutics shareholders |
